A group of biopharmaceutical and health care investors warned lawmakers Monday that Congress' drug-pricing bill, if passed as currently written, could disincentivize investment in small-molecule drugs, including 81 drugs being developed by Massachusetts-based companies, and trigger the loss of hundreds of thousands of jobs.
